key: cord-0885815-u8t8i73r authors: Cabrera Martimbianco, Ana Luiza; Pacheco, Rafael Leite; Bagattini, Ângela Maria; Riera, Rachel title: Frequency, signs and symptoms, and criteria adopted for long COVID‐19: A systematic review date: 2021-06-02 journal: Int J Clin Pract DOI: 10.1111/ijcp.14357 sha: b63d62d2eed000ebd6f690f30ee8a523fec26094 doc_id: 885815 cord_uid: u8t8i73r AIMS: To identify, systematically evaluate and summarise the best available evidence on the frequency of long COVID‐19 (post‐acute COVID‐19 syndrome), its clinical manifestations, and the criteria used for diagnosis. METHODS: Systematic review conducted with a comprehensive search including formal databases, COVID‐19 or SARS‐CoV‐2 data sources, grey literature, and manual search. We considered for inclusion clinical trials, observational longitudinal comparative and non‐comparative studies, cross‐sectional, before‐and‐after, and case series. We assessed the methodological quality by specific tools based on the study designs. We presented the results as a narrative synthesis regarding the frequency and duration of long COVID‐19, signs and symptoms, criteria used for diagnosis, and potential risk factors. RESULTS: We included 25 observational studies with moderate to high methodological quality, considering 5440 participants. The frequency of long COVID‐19 ranged from 4.7% to 80%, and the most prevalent signs/symptoms were chest pain (up to 89%), fatigue (up to 65%), dyspnea (up to 61%), and cough and sputum production (up to 59%). Temporal criteria used to define long COVID‐19 varied from 3 to 24 weeks after acute phase or hospital discharge. Potentially associated risk factors were old age, female sex, severe clinical status, a high number of comorbidities, hospital admission, and oxygen supplementation at the acute phase. However, limitations related to study designs added uncertainty to this finding. None of the studies assessed the duration of signs/symptoms. CONCLUSION: The frequency of long COVID‐19 reached up to 80% over the studies included and occurred between 3 and 24 weeks after acute phase or hospital discharge. Chest pain, fatigue, dyspnea, and cough were the most reported clinical manifestations attributed to the condition. Based on these systematic review findings, there is an urgent need to understand this emerging, complex and challenging medical condition. Proposals for diagnostic criteria and standard terminology are welcome. Long COVID-19 is a term used to describe the condition presented by individuals who have recovered from the acute phase of COVID-19 but are still reporting lasting effects of the infection or having had the usual clinical picture for much longer than expected, or have new symptoms and signs. Two presentations of this condition have been observed: (a) a severe form, with the occurrence of thromboembolic complications, for example: and (b) a nonspecific form, usually emphasised by fatigue and dyspnea. 1 The clinical management of cases requires an approach that considers the severity and its prognosis and impact on affected individuals' quality of life. Researchers, healthcare managers, and health professionals have now discussed the challenge of rehabilitating patients facing a disease with a plethora of clinical presentation. 2, 3 Studies have sought to understand the convalescent phase of the COVID-19 better. 4, 5 One of the critical issues for these achievements is identifying the frequency, defining criteria for diagnosis, and understanding the spectrum and severity of clinical manifestations observed in long . From this knowledge, preventive and therapeutic measures can be investigated and implemented, either at the individual or population level. To scientifically and impartially inform healthcare decision making, we developed a systematic review to map and critically evaluate the available information on the frequency of long COVID-19 and the characteristics of its clinical manifestations. To identify, systematically evaluate and summarise the best available evidence on the frequency of long COVID-19, the characteristics of its clinical manifestations, and the adopted criteria for its diagnosis. A systematic review conducted in the Health Technology Assessment Center at Hospital Sírio-Libanês, São Paulo, SP, Brazil. The protocol was prospectively registered in the PROSPERO database (CRD42020214587, available from https://www.crd.york.ac.uk/ prosp ero/displ ay_record.php?ID=CRD42 02021 4587). The review's planning and conduct were carried out following the Cochrane Handbook for Systematic Reviews of Interventions, 6 considering those sections relevant for a systematic review of frequency. The report of the review was prepared following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement. 7 Considering the research question and the outcomes of interest, we searched for the following study designs: • Experimental studies: randomised, quasi-randomised or nonrandomised trials. • Observational longitudinal comparative studies (cohort or case-control). • Observational non-comparative studies (case series, case studies reporting the experience of a specific service). • Cross-sectional studies (prevalence, survey, or analytical cross-sectional). • Uncontrolled before-and-after studies (including interrupted time series with two or more measures before and after the event of interest). • Controlled before-and-after studies. Review criteria: how did you gather, select and analyze the information you considered in your review? • Systematic review conducted with a comprehensive search including formal databases, COVID-19 or SARS-CoV-2 data sources, grey literature, and manual search. • We considered for inclusion clinical trials, observational longitudinal comparative and non-comparative studies, cross-sectional, before-and-after and case series. • We presented the results as a narrative synthesis regarding frequency and duration of long COVID, signs and symptoms, criteria used for diagnosis, and potential risk factors. Message for the clinic: what is the 'take-home' message for the clinician? • The frequency of long COVID reached up to 80% over the studies included and occurred between 3 to 24 weeks after acute phase or hospital discharge. Chest pain, fatigue, dyspnea and cough were the most reported clinical manifestations attributed to the condition. • Temporal criteria used to define long COVID varied from 3 to 24 weeks after acute phase or hospital discharge. • Based on this systematic review findings, there is an urgent need to understand this emerging, complex and challenging medical condition. Proposals for diagnostic criteria and standard terminology are welcome. Reports of a single individual case were excluded. Studies available only as preprint versions and without a peer-review process were not considered for this systematic review. For those studies comparing participants with vs without COVID-19, we restricted our analyses for the COVID-19 participants (population of interest for this review), and they were treated as single-arm cohort studies. • Frequency of long COVID-19, or post-acute COVID-19 or persistence of clinical manifestations after the acute phase (defined by the authors of primary studies). • Frequency of signs and symptoms experienced by patients after COVID-19 acute phase. Given the lack of a worldwide accepted definition and to avoid redundancy, we adopted the term "long COVID" to refer to long COVID-19, post-acute COVID-19 or persistence of signs and symptoms after the COVID-19 acute phase. This assumption will be addressed henceforth under the discussion section. We conducted a sensitive search of the literature to identify any study that would meet the eligibility criteria. There were no reser- The procedure for selecting studies was carried out in two phases within the Rayyan platform. 8 In the first phase, two reviewers independently evaluated all titles and abstracts retrieved by the searches. References deemed "potentially eligible" were then for the second phase (full-text assessment) to confirm its eligibility. The risk of bias assessment was performed on the premises of the study design as presented below: • Randomised clinical trials (Cochrane Risk of Bias tool). 6 • Cohort or case-control, non-randomised trials: ROBINS-I. 9 • Controlled before-and-after study: ROBINS-I with additional issues for (controlled) before-after studies. 9 • Uncontrolled before and after the study (including interrupted time series): ROBINS-I with additional issues for (uncontrolled) before-after studies. 9 • Analytical cross-sectional study: the Joanna Briggs Institute checklist for analytical cross-sectional studies. 10 • Prevalence cross-sectional study: the Joanna Briggs Institute checklist for prevalence studies. 11 • Case series or single-arm cohort: National Institute of Health. Quality Assessment Tool for Case Series Studies. 12 Considering the frequency of compliance with the relevant items, at the discretion of the review authors, the studies were categorised as presenting high quality (80% or more of accomplished items), moderate quality (≥50% to <70%) or low quality (<50%). For cohort studies including a non-COVID-19 comparison group and those cohort studies that did not provide any comparable data from the group not experiencing long COVID-19, we used the NIH tool for case series, assuming that this tool could be more suitable. Two independent reviewers carried the evaluation out and a third reviewer solved any dissension. We created a table comprising the methodological characteristics, main findings, and funding sources from each included study. Whenever data were available, we presented the frequency of long COVID-19, the criteria used for diagnosis, the description, frequency and duration of signs and symptoms, and risk factors suspected to be related to long COVID-19 occurrence. We presented the results using a narrative approach (qualitative synthesis) for the outcomes: frequency of long COVID-19, frequency of signs and symptoms, frequency of different criteria used for the definition of long COVID-19, and mean duration of the long COVID-19 along the primary studies included. For the outcome' risk factors for long COVID', depending on data availability of data and homogeneity of studies, we planned to pool results from similar studies by random-effects metaanalyses (software Review Manager 5.4). We planned to estimate the risk ratios (or odds ratios) for dichotomous data assuming a 95% confidence interval. As the meta-analysis was not possible, we presented the results as qualitative synthesis (descriptive presentation). In this case, we planned to use tables comprising the main findings of the included studies and their methodological quality or risk of bias. The search strategies retrieved 22 361 records and 1.680 identical duplicates were removed previously to the selection process. After the reading titles and abstracts (first phase), 20 641 references did not fit the inclusion criteria considering the review's PICO and were eliminated. The full text of the 40 remained records was read (second phase), 12 of which were excluded [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] (Table S2) The 25 included studies comprised a total sample of 5440 participants. We detailed the main characteristics of the studies in Ongoing studies (n = 2) Eliminated duplicates (n = 1,680) Manual search (n = 1) Author For all included studies, we used the National Institute of Health. None of the included studies assessed the duration of signs and symptoms attributed to long COVID-19. Fourteen studies [25] [26] [27] [28] [31] [32] [33] 35, 39, 43, 44, [47] [48] [49] reported some aspects investigated as potential risk factor for long COVID-19 (Table 1) . The most prevalent aspects of persistent symptoms were old age, female sex, severe clinical status at acute phase, high number of comorbidities, hospital admission, and oxygen supplementation at the acute phase. Table S4 shows the detailed results from studies on the risk factors potentially associated with long COVID-19. chronic COVID-19 as extending beyond 12 weeks. 1 Thereby, considering the lack of consensus, our review findings provide a robust basis for mathematical models for diagnostic and predictive aspects that could be addressed by further studies. Most of the signs and symptoms attributed to long COVID-19 could be found in the current pandemic scenario and non-COVID-19 individuals. Social isolation, modified lifestyle habits, reduced physical activity, social and economic insecurity may contribute to physical and psychological manifestations. This issue constitutes an important confounding factor that the included studies could not Long COVID-19 or post-acute COVID-19 or persistent sign/symptom 4.7-80.0 Carfi (2020), 4 Carvalho-Scheneider (2020), 26 Huang (2020), 31 Jacobs (2020), 32 Lu (2020), 34 Moreno-Perez (2021), 35 Nehme (2020), 36 Petersen (2020), 39 Rosales-Castillo (2021), 42 Tarazona-Fernandez (2020) 46 Ageusia/dysgeusia 1.0-21.6 Bellan (2021), 25 Carfi (2020), 4 Carvalho-Scheneider (2020); 26 Garrigues (2020), 28 Huang (2021), 31 Jacobs (2020), 32 Liang (2020), 33 Lu (2020), 34 Moreno-Perez (2021), 35 Nehme (2020), 36 Petersen (2020), 39 , Rosales-Castillo (2021), 42 Suarez-Robles (2020), 45 Zhao (2020) 49 Anosmia 0.0-26.2 Bellan (2021), 25 Carfi (2020), 4 Carvalho-Scheneider (2020), 26 Garrigues (2020), 28 Guedj (2020), 29 Huang (2021), 31 Jacobs (2020), 32 Lu (2020), 34 Moreno-Perez (2021), 35 Nehme (2020), 36 Otte (2020a, 37 Otte 2020b 38 ), Petersen (2020), 39 Rosales-Castillo (2021), 42 ,Suarez-Robles (2020), 45 Tarazona-Fernandez (2020), 46 Van den Borst (2020), 47 Xiong (2021), 48 Zhao (2020) 49 Arthralgia 5.9-54.7 Bellan (2021), 25 Carfi (2020), 4 Carvalho-Scheneider (2020), 26 Huang (2021), 31 Jacobs (2020), 32 Petersen (2020), 39 Suarez-Robles (2020), 45 Tarazona-Fernandez (2020), 46 Xiong (2021) (2020), 4 Carvalho-Scheneider (2020), 26 Huang (2021), 31 Liang (2020), 33 Tarazona-Fernandez (2020), 46 Xiong (2021) Cognitive/memory/concentration impairment 18.0-57.1 Garrigues (2020), 28 Guedj (2020), 29 Halpin (2020), 30 Jacobs (2020), 32 Lu (2020), 34 Moreno-Perez (2021), 35 Ramani (2021), 41 Van den Borst (2020), 47 Xiong (2021) 48 Communication difficulty 6.0 Halpin (2020) 30 Cough/sputum production 1.8-59.0 Bellan (2021), 25 Carfi (2020), 4 Garrigues (2020), 28 Halpin (2020), 30 Jacobs (2020), 32 Liang (2020), 33 Moreno-Perez (2021), 35 Nehme (2020), 36 Rosales-Castillo (2021), 42 Suarez-Robles (2020), 45 Tarazona-Fernandez (2020), 46 Xiong (2021), 48 Zhao (2020) 49 Cutaneous signs 1.5-20.0 Carvalho-Scheneider (2020), 26 Huang (2021), 31 Jacobs (2020), 32 Suarez-Robles (2020) 45 Diarrhoea/vomiting/gastrointestinal symptoms 1.3-33.3 Bellan (2021), 25 Carfi (2020), 4 Huang (2021), 31 Jacobs (2020), 32 Liang (2020), 33 Moreno-Perez (2021), 35 Nehme (2020), 36 Tarazona-Fernandez (2020), 46 Zhao (2020) 49 Depression/anxiety 3.0-25.0 El Sayed (2020), 27 Huang (2021), 31 Ramani (2021), 41 Tarazona-Fernandez (2020), 46 Van den Borst (2020) 47 Dyspnea/breathlessness 5.5-61.0 Bellan (2021), 25 Carfi (2020), 4 Carvalho-Scheneider (2020), 26 Garrigues (2020), 28 Guedj (2020), 29 Halpin (2020), 30 Huang (2021), 31 Jacobs (2020), 32 Liang (2020), 33 Moreno-Perez (2021), 35 Nehme (2020), 36 Rosales-Castillo (2021), 42 Suarez-Robles (2020), 45 Tarazona-Fernandez (2020), 46 Van den Borst (2020), 47 Zhao (2020) 49 Fatigue/asthenia 6.6-64.0 Carfi (2020), 4 Carvalho-Scheneider (2020), 26 El Sayed (2020), 27 Garrigues (2020), 28 Halpin (2020), 30 Huang (2021), 31 Jacobs (2020), 32 Liang (2020), 33 Lu (2020), 34 Moreno-Perez (2021), 35 Nehme (2020), 36 Petersen (2020), 39 Rosales-Castillo (2021), 42 Simani (2021), 44 Suarez-Robles (2020), 45 Tarazona-Fernandez (2020), 46 Zhao (2020) 49 Faecal incontinency 3.0 Halpin (2020) 30 Fever 0.0-20.0 Huang (2021), 31 Jacobs (2020), 32 Liang (2020), 33 Nehme (2020), 36 Petersen (2020), 39 Tarazona-Fernandez (2020) 46 Functional impairment 5.7-50.0 Bellan (2021), 25 Suarez-Robles (2020) 45 Hair loss 20.0-28.6 Garrigues (2020), 28 Huang (2021), 31 Xiong (2021) 48 Headache 2.0-39.0 Carfi (2020), 4 Carvalho-Scheneider (2020), 26 Huang (2021), 31 Jacobs (2020), 32 Lu (2020), 34 Moreno-Perez (2021), 35 Nehme (2020), 36 Petersen (2020), 39 Suarez-Robles (2020), 45 Tarazona-Fernandez (2020) 46 Hearing loss 1.6 Lu (2020) 34 (Continues) rule out because of the non-comparative design and the lack of data for those studies with a non-COVID-19 comparator group. 25 Carfi (2020), 4 Carvalho-Scheneider (2020), 26 Huang (2021), 31 Jacobs (2020), 32 Lu (2020), 34 Moreno-Perez (2021), 35 Rosales-Castillo (2021), 42 Tarazona-Fernandez (2020), 46 Xiong (2021) 48 Pain and discomfort 19.0-66.0 Guedj (2020), 29 Halpin (2020), 30 Huang (2021) 31 Palpitations 9.0-62.0 Carvalho-Scheneider (2020), 26 Huang (2021), 31 Liang (2020), 33 Suarez-Robles (2020) 45 Physical dysfunction 4.0-28.3 Ramani (2021), 41 Suarez-Robles (2020), 45 Van den Borst (2020), 47 Xiong (2021) 48 Post-traumatic stress/psychosocial symptoms/mood changes 5.8-57.1 Bellan (2021), 25 Halpin (2020), 30 Lu (2020), 34 Puchner (2021), 40 Simani (2021) Sleep disorder/insomnia 21.7-53.0 Garrigues (2020), 28 Guedji (2020), 29 Huang (2021), 31 Puchner (2021), 40 Ramani (2021) 41 Sensitivity disorder 7.5 Suarez-Robles (2020) 45 Sore throat/throat pain 3.2-11.0 Carfi (2020), 4 Halpin (2020), 30 Huang (2021), 31 Tarazona-Fernandez (2020), 46 Xiong (2021) The consumption of additional resources allocated to long COVID-19 can be estimated from information about the disease's frequency, its main manifestations, and duration. Preventive strategies can also be adopted based on the recognition of associated risk factors. Based on the findings that respiratory manifestations and fatigue were the most frequent clinical findings attributed to long COVID-19 over the studies identified, rehabilitation services can be restructured, and health systems can be prepared to receive patients with these needs. This review opens up several questions that need to be addressed by further studies. One of them refers to the underrepresentation of low-and middle-income countries in the studies conducted so far, and it is precisely in those settings where the pandemic and the long COVID-19 has had a more substantial impact on health resources and quality of life. Additionally, it is necessary to define the set of signs and symptoms that are most likely to be part of this new medical condition, its duration, and the acute phase's temporal criteria. It would allow new studies to estimate its prevalence and incidence in a more precise and more standardised way, minimising confounding factors. As key messages from our findings, we emphasise that: (a) there is an urgent need to understand this emerging, complex, and We would like to thank Michelle Quarti Rosa for her contribution during the protocol upload in the PROSPERO database. The authors declare no competing interests. Management of post-acute covid-19 in primary care Predictive factors for a new positive nasopharyngeal swab among patients recovered from covid-19 Gemelli Against COVID-19 Post-Acute Care Study Group. Post-COVID-19 global health strategies: the need for an interdisciplinary approach Gemelli against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19 Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate Health Care Systems Network -United States Cochrane handbook for systematic reviews of interventions version 6.0 (updated Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement Rayyan-a web and mobile app for systematic reviews ROBINS-I: a tool for assessing risk of bias in non-randomized studies of interventions Checklist for cross sectional studies Checklist for prevalence studies Quality assessment tool for case series studies 6-month SARS-CoV-2 antibody persistency in a Tyrolian COVID-19 cohort Developing services for long COVID: lessons from a study of wounded healers Longitudinal clinical and radiographic evaluation reveals interleukin-6 as an indicator of persistent pulmonary injury in COVID-19 Autonomic dysfunction in 'long COVID': rationale, physiology and management strategies Post-COVID-19 syndrome? New daily persistent headache in the aftermath of COVID-19 Persistent symptoms after Covid-19: qualitative study of 114 "long Covid" patients and draft quality principles for services. BMC Rehabilitation needs of the first cohort of post-acute COVID-19 patients in Hubei, China SARS-CoV-2, a virus with many faces: a series of cases with prolonged persistence of COVID-19 symptoms Post-COVID-19 follow-up clinic: depicting chronicity of a new disease British Thoracic Society survey of rehabilitation to support recovery of the post-COVID-19 population Factors associated with the duration of hospitalization among COVID-19 patients in Vietnam: a survival analysis Could cognitive behavioural therapy be an effective treatment for long COVID and post COVID-19 fatigue syndrome? Lessons from the Qure study for Q-fever fatigue syndrome Respiratory and psychophysical sequelae among patients with COVID-19 four months after hospital discharge Follow-up of adults with noncritical COVID-19 two months after symptom onset Post-COVID-19 fatigue and anhedonia: a cross-sectional study and their correlation to post-recovery period Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19 18F-FDG brain PET hypometabolism in patients with long Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: a crosssectional evaluation 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study Persistence of symptoms and quality of life at 35 days after hospitalization for COVID-19 infection Three-month follow-up study of survivors of coronavirus disease 2019 after discharge Cerebral micro-structural changes in COVID-19 patients -an MRI-based 3-month follow-up study Post-acute COVID-19 syndrome. Incidence and risk factors: a Mediterranean cohort study COVID-19 symptoms: longitudinal evolution and persistence in outpatient settings Olfactory dysfunction in patients after recovering from COVID-19 Persisting olfactory dysfunction in patients after recovering from COVID-19 Long COVID in the Faroe Islands: a longitudinal study among nonhospitalized patients Beneficial effects of multidisciplinary rehabilitation in post-acute COVID-19 -an observational cohort study Post-ICU COVID-19 outcomes: a case series Persistent symptoms after acute COVID-19 infection: importance of follow-up. Persistencia de manifestaciones clínicas tras la infección COVID-19: importancia del seguimiento Post-COVID-19 Cholangiopathy: a novel entity Prevalence and correlates of chronic fatigue syndrome and post-traumatic stress disorder after the outbreak of the COVID-19 Ninety days posthospitalization evaluation of residual COVID-19 symptoms through a phone call check list ¿Enfermedad prolongada o secuela pos-COVID-19? Prolonged disease or post-COVID-19 sequela Comprehensive health assessment three months after recovery from acute COVID-19 Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery Post-acute COVID-19 syndrome